Compare AENT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | FHTX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.4M | 360.8M |
| IPO Year | N/A | 2020 |
| Metric | AENT | FHTX |
|---|---|---|
| Price | $7.10 | $5.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $10.00 | ★ $11.43 |
| AVG Volume (30 Days) | 61.0K | ★ 204.4K |
| Earning Date | 02-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.70 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,088,441,000.00 | $24,518,000.00 |
| Revenue This Year | $8.23 | $40.91 |
| Revenue Next Year | $2.26 | $11.87 |
| P/E Ratio | $16.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.21 | $2.95 |
| 52 Week High | $8.80 | $6.95 |
| Indicator | AENT | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.69 |
| Support Level | N/A | $5.18 |
| Resistance Level | N/A | $5.79 |
| Average True Range (ATR) | 0.00 | 0.34 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 27.15 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.